๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Crizotinib

Also listed in trial records as Xalkori
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 10 trials in our China, USA, UK and India registers that name Crizotinib as an intervention. Synced 24 Sep 2026
10Trials tracked
4Recruiting now
8Lead sponsors
4Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards

Crizotinib is named as a drug or biological intervention in 10 clinical trials in our China, USA, UK and India trial registers, 4 of which are recruiting. Lead sponsors include IDEAYA Biosciences (3), Xcovery Holdings, Inc. (1) and Pfizer (1). Registered phases: Phase 3, Phase 2/3, Phase 1/2 and Observational. Conditions studied include Carcinoma, Non-Small-Cell Lung; Metastatic Uveal Melanoma; Non Small Cell Lung Cancer.

01

Clinical trials of Crizotinib

10 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT06564324 A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients (ClinicalTrials.gov ↗)
Non Small Cell Lung Cancer
Phase 3 Recruiting Nuvation Bio Inc. China
NCT07804186 Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma (ClinicalTrials.gov ↗)
Uveal Melanoma
Phase 3 Recruiting IDEAYA Biosciences USA
NCT03947385 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (ClinicalTrials.gov ↗)
Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer
Phase 1/2 Recruiting IDEAYA Biosciences USA
NCT05467189 Antineoplastic Drugs in Elderly Patients (ClinicalTrials.gov ↗)
Cancer
Observational Recruiting Shandong University China
NCT02767804 eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer
Phase 3 Active, closed Xcovery Holdings, Inc. UK, USA, China
NCT03052608 A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC (ClinicalTrials.gov ↗)
Carcinoma, Non-Small-Cell Lung
Phase 3 Active, closed Pfizer UK, USA, India, China
NCT04603807 A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
Carcinoma, Non-Small-Cell Lung
Phase 3 Active, closed Hoffmann-La Roche India, China
NCT06082635 TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC) (ClinicalTrials.gov ↗)
Non Small Cell Lung Cancer
Phase 3 Active, closed Shenzhen TargetRx Co., Ltd. China
NCT06140836 A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naรฏve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) (ClinicalTrials.gov ↗)
Carcinoma, Non-Small-Cell Lung
Phase 3 Active, closed Bristol-Myers Squibb USA, India, China
NCT05987332 IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma (ClinicalTrials.gov ↗)
Metastatic Uveal Melanoma
Phase 2/3 Active, closed IDEAYA Biosciences UK, USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

9 conditions
Condition (as registered)Trials
Carcinoma, Non-Small-Cell Lung3
Metastatic Uveal Melanoma2
Non Small Cell Lung Cancer2
Non-small Cell Lung Cancer1
Cutaneous Melanoma1
Colorectal Cancer1
Other Solid Tumors1
Uveal Melanoma1
Cancer1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
IDEAYA Biosciences3
Xcovery Holdings, Inc.1
Pfizer1
Bristol-Myers Squibb1
Hoffmann-La Roche1
Shandong University1
Shenzhen TargetRx Co., Ltd.1
Nuvation Bio Inc.1
04

Trials by country register

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how Crizotinib works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Crizotinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.